MCID: BRR002
MIFTS: 39

Barrett's Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Barrett's Adenocarcinoma

MalaCards integrated aliases for Barrett's Adenocarcinoma:

Name: Barrett's Adenocarcinoma 12 15 73
Adenocarcinoma Arising in Barrett's Mucosa 12
Barrett Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7941
NCIt 50 C7027
UMLS 73 C1332460

Summaries for Barrett's Adenocarcinoma

MalaCards based summary : Barrett's Adenocarcinoma, also known as adenocarcinoma arising in barrett's mucosa, is related to adenocarcinoma and protoplasmic astrocytoma. An important gene associated with Barrett's Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Endometrial cancer and Glioma. The drugs acetic acid and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and colon, and related phenotypes are cellular and behavior/neurological

Related Diseases for Barrett's Adenocarcinoma

Diseases related to Barrett's Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 127)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 29.8 CDKN2A ERBB2 KRAS PTGS2 TP53
2 protoplasmic astrocytoma 10.3 PTGS2 TP53
3 gastric papillary adenocarcinoma 10.3 ERBB2 TP53
4 pleomorphic adenoma carcinoma 10.3 ERBB2 TP53
5 non-proliferative fibrocystic change of the breast 10.2 ERBB2 TP53
6 uterine corpus serous adenocarcinoma 10.2 ERBB2 TP53
7 breast squamous cell carcinoma 10.2 ERBB2 TP53
8 uterine body mixed cancer 10.2 ERBB2 TP53
9 bladder squamous cell carcinoma 10.2 CDKN2A TP53
10 keratinizing squamous cell carcinoma 10.2 CDKN2A TP53
11 breast papillomatosis 10.2 CDKN2A ERBB2
12 spitz nevus 10.2 CDKN2A TP53
13 fallopian tube endometrioid adenocarcinoma 10.2 CDKN2A ERBB2
14 bowenoid papulosis 10.2 CDKN2A PTGS2
15 bladder carcinoma in situ 10.2 CDKN2A TP53
16 vulva squamous cell carcinoma 10.2 CDKN2A TP53
17 scrotal carcinoma 10.2 CDKN2A TP53
18 glioma susceptibility 1 10.2 ERBB2 TP53
19 vulvar disease 10.2 CDKN2A TP53
20 bartholin's gland disease 10.2 CDKN2A TP53
21 vulval paget's disease 10.2 CDKN2A ERBB2
22 microglandular adenosis 10.2 ERBB2 TP53
23 anal squamous cell carcinoma 10.2 CDKN2A TP53
24 glycogen-rich clear cell breast carcinoma 10.2 CDKN2A TP53
25 balanitis xerotica obliterans 10.2 CDKN2A PTGS2
26 gastric adenosquamous carcinoma 10.2 CDKN2A TP53
27 anogenital venereal wart 10.2 CDKN2A TP53
28 vulva adenocarcinoma 10.2 CDKN2A ERBB2
29 cervix uteri carcinoma in situ 10.2 CDKN2A TP53
30 uterus carcinoma in situ 10.2 CDKN2A TP53
31 oral leukoplakia 10.2 CDKN2A TP53
32 meningeal melanomatosis 10.2 CDKN2A TP53
33 papilledema 10.2 OGG1 TP53
34 breast benign neoplasm 10.2 ERBB2 TP53
35 thoracic benign neoplasm 10.2 ERBB2 TP53
36 dedifferentiated liposarcoma 10.2 CDKN2A TP53
37 uterine corpus cancer 10.2 ERBB2 TP53
38 rare adenocarcinoma of the breast 10.2 KRAS TP53
39 endocervical adenocarcinoma 10.2 CDKN2A TP53
40 hyperplastic polyposis syndrome 10.2 KRAS TP53
41 esophagus adenocarcinoma 10.2 ERBB2 PTGS2 TP53
42 mutyh-associated polyposis 10.2 KRAS TP53
43 ductal carcinoma in situ 10.2 ERBB2 PTGS2 TP53
44 stomach disease 10.2 ERBB2 PTGS2 TP53
45 uterine carcinosarcoma 10.2 ERBB2 PTGS2 TP53
46 penile disease 10.1 CDKN2A TP53
47 actinic keratosis 10.1 CDKN2A PTGS2 TP53
48 tonsil cancer 10.1 CDKN2A ERBB2 TP53
49 pre-malignant neoplasm 10.1 CDKN2A ERBB2 TP53
50 mature teratoma 10.1 KRAS TP53

Graphical network of the top 20 diseases related to Barrett's Adenocarcinoma:



Diseases related to Barrett's Adenocarcinoma

Symptoms & Phenotypes for Barrett's Adenocarcinoma

MGI Mouse Phenotypes related to Barrett's Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.11 ADIPOR1 ADIPOR2 CDKN2A ERBB2 KRAS OGG1
2 behavior/neurological MP:0005386 10.08 ADIPOR1 ADIPOR2 CDKN2A ERBB2 KRAS OGG1
3 homeostasis/metabolism MP:0005376 10.02 ADIPOR1 ADIPOR2 CDKN2A ERBB2 FHIT KRAS
4 digestive/alimentary MP:0005381 9.91 CDKN2A ERBB2 FHIT KRAS PTGS2 TP53
5 embryo MP:0005380 9.88 CDKN2A ERBB2 KRAS PTGS2 RAD51 TP53
6 integument MP:0010771 9.8 CDKN2A ERBB2 FHIT KRAS PTGS2 TP53
7 liver/biliary system MP:0005370 9.8 ADIPOR1 ADIPOR2 CDKN2A KRAS OGG1 PTGS2
8 muscle MP:0005369 9.63 ADIPOR1 CDKN2A ERBB2 KRAS PTGS2 TP53
9 neoplasm MP:0002006 9.5 CDKN2A ERBB2 FHIT KRAS OGG1 PTGS2
10 skeleton MP:0005390 9.17 ADIPOR1 ADIPOR2 CDKN2A ERBB2 KRAS PTGS2

Drugs & Therapeutics for Barrett's Adenocarcinoma

Drugs for Barrett's Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
acetic acid Approved 64-19-7 176
2
Racepinephrine Approved Not Applicable 329-65-7 838
3
Epinephrine Approved, Vet_approved Not Applicable 51-43-4 5816
4
Vitamin A Approved, Nutraceutical, Vet_approved 11103-57-4, 68-26-8 445354
5 Adjuvants, Immunologic
6 Immunologic Factors
7 Retinol palmitate
8
Retinol acetate 127-47-9 10245972
9 retinol
10 Protective Agents
11 Epinephryl borate Not Applicable

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Aceto-whitening in the Assessment of Gastrointestinal Neoplasia Unknown status NCT01618643
2 ESD Versus EMR for Treatment of Early Barrett`s Adenocarcinoma Completed NCT01871636 Not Applicable
3 Neoplastic Barrett Esophagus: Endoscopic Piecemeal vs. En Bloc Resection Recruiting NCT03427346 Not Applicable
4 Endoscopic Mucosal Resection and Cellular Matrix Enrolling by invitation NCT03240679 Not Applicable

Search NIH Clinical Center for Barrett's Adenocarcinoma

Genetic Tests for Barrett's Adenocarcinoma

Anatomical Context for Barrett's Adenocarcinoma

MalaCards organs/tissues related to Barrett's Adenocarcinoma:

41
Bone, Lung, Colon, Ovary, Cervix, Thyroid, Lymph Node

Publications for Barrett's Adenocarcinoma

Articles related to Barrett's Adenocarcinoma:

(show top 50) (show all 98)
# Title Authors Year
1
Genome-Wide Analysis of Barrett's Adenocarcinoma. A First Step Towards Identifying Patients at Risk and Developing Therapeutic Paths. ( 29223109 )
2018
2
Treatment of long-segment Barrett's adenocarcinoma by complete circular endoscopic submucosal dissection: a case report. ( 29351773 )
2018
3
Minimally invasive esophagectomy for Barrett's adenocarcinoma. ( 30505964 )
2018
4
Buried Barrett's Adenocarcinoma Clearly Demonstrated with Acetic Acid Chromoendoscopy. ( 30166635 )
2018
5
Endoscopic Treatment of Early Barrett's Adenocarcinoma and Dysplasia: Focus on Submucosal Cancer. ( 30176662 )
2018
6
Reduced αGlcNAc glycosylation on gastric gland mucin is a biomarker of malignant potential for gastric cancer, Barrett's adenocarcinoma, and pancreatic cancer. ( 29658052 )
2018
7
Tumor location is a risk factor for lymph node metastasis in superficial Barrett's adenocarcinoma. ( 28924592 )
2017
8
Impact of RAD51C-mediated Homologous Recombination on Genomic Integrity in Barrett's Adenocarcinoma Cells. ( 29399538 )
2017
9
Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma Cells. ( 27932981 )
2016
10
A case of Barrett's adenocarcinoma with marked endoscopic morphological changes in Barrett's esophagus over a long follow-up period of 15a88years. ( 26946036 )
2016
11
A case of simultaneous esophageal squamous cell carcinoma and Barrett's adenocarcinoma. ( 27220657 )
2016
12
Single center experience of endoscopic submucosal dissection (ESD) in early Barrett's adenocarcinoma. ( 25294533 )
2015
13
Clinical outcomes of endoscopic submucosal dissection for superficial Barrett's adenocarcinoma. ( 24565073 )
2014
14
The evil lies below the surface: Subsquamous tumor extension in Barrett's adenocarcinoma. ( 26134612 )
2014
15
Ischemic heart disease, factor predisposing to Barrett's adenocarcinoma: A case control study. ( 25133047 )
2014
16
Volumetric laser endomicroscopy detects subsquamous Barrett's adenocarcinoma. ( 24496431 )
2014
17
Differences in the Characteristics of Barrett's Esophagus and Barrett's Adenocarcinoma between the United States and Japan. ( 23606979 )
2013
18
A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft model. ( 23288782 )
2013
19
Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth. ( 23604115 )
2013
20
Reduced expression of I+GlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma - a possible biomarker to predict the malignant potential of Barrett's oesophagus. ( 24117499 )
2013
21
Small Barrett's adenocarcinoma, 3 mm in size, in long-segment Barrett's esophagus detected after 4 years of follow up. ( 23617677 )
2013
22
Current status of endoscopic diagnosis and treatment of superficial Barrett's adenocarcinoma in Asia-Pacific region. ( 23617667 )
2013
23
Barrett's adenocarcinoma in long-segment Barrett's esophagus successfully detected by narrow-band imaging with magnifying endoscopy. ( 23617678 )
2013
24
Increased expression of the 5-lipoxygenase pathway and its cellular localization in Barrett's adenocarcinoma. ( 22690932 )
2012
25
Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth. ( 22399496 )
2012
26
Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma. ( 23180947 )
2012
27
MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett's adenocarcinoma. ( 22365974 )
2012
28
Barrett's adenocarcinoma of the esophagus: better outcomes through new methods of diagnosis and treatment. ( 21629515 )
2011
29
How much length of the distal esophagus is removed by transhiatal approach for squamous cell carcinoma and Barrett's adenocarcinoma in Japanese patients? ( 22234066 )
2011
30
Human Barrett's adenocarcinoma of the esophagus, associated myofibroblasts, and endothelium can arise from bone marrow-derived cells after allogeneic stem cell transplant. ( 20677919 )
2011
31
Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome. ( 21423218 )
2011
32
A rare case of Barrett's adenocarcinoma including squamous cell carcinoma component. ( 26190613 )
2011
33
Barrett's adenocarcinoma 52 years after subtotal esophagectomy for pediatric peptic stricture. ( 20103354 )
2010
34
A case of early Barrett's adenocarcinoma repeatedly developing multiple metachronous lesions shortly after endoscopic therapy: an analysis for genetic and epigenetic alterations. ( 20650453 )
2010
35
Genome-wide analysis of genetic alterations in Barrett's adenocarcinoma using single nucleotide polymorphism arrays. ( 18663352 )
2009
36
Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort. ( 19620873 )
2009
37
Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett's adenocarcinoma, the definition of Barrett's esophagus, and histologic criteria for mucosal adenocarcinoma or high-grade dysplasia. ( 19828957 )
2009
38
Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. ( 18676772 )
2008
39
Corn-derived carbohydrate inositol hexaphosphate inhibits Barrett's adenocarcinoma growth by pro-apoptotic mechanisms. ( 18202808 )
2008
40
No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study. ( 18349297 )
2008
41
Comparison of DNA histograms by standard flow cytometry and image cytometry on sections in Barrett's adenocarcinoma. ( 18513411 )
2008
42
Results of a multimodal therapy in patients with stage IV Barrett's adenocarcinoma. ( 18802733 )
2008
43
Immunohistochemical expression of p63 in esophageal Barrett's adenocarcinoma. ( 21479434 )
2008
44
Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. ( 17376806 )
2007
45
Usefulness of magnifying endoscopy with narrow band imaging for the detection of specialized intestinal metaplasia in columnar-lined esophagus and Barrett's adenocarcinoma. ( 17185078 )
2007
46
Familial trends of inheritance in gastro esophageal reflux disease, Barrett's esophagus and Barrett's adenocarcinoma: 20 families. ( 17227311 )
2007
47
Familial Barrett's adenocarcinoma. ( 16542304 )
2006
48
Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis. ( 16921482 )
2006
49
NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. ( 17244951 )
2006
50
Angiogenic switch in Barrett's adenocarcinoma: the role of vascular endothelial growth factor. ( 16720317 )
2006

Variations for Barrett's Adenocarcinoma

Copy number variations for Barrett's Adenocarcinoma from CNVD:

7 (show top 50) (show all 60)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 39411 10 114900000 119100000 Gain ABLIM1 Barrett''s adenocarcinoma
2 39412 10 114900000 119100000 Gain AFAP1L2 Barrett''s adenocarcinoma
3 42467 10 34500000 38800000 Gain CCNY Barrett''s adenocarcinoma
4 42468 10 34500000 38800000 Gain CUL2 Barrett''s adenocarcinoma
5 65755 12 21200000 26300000 Gain SSPN Barrett''s adenocarcinoma
6 66184 12 26300000 27700000 Gain ARNTL2 Barrett''s adenocarcinoma
7 66185 12 26300000 27700000 Gain TM7SF3 Barrett''s adenocarcinoma
8 73111 12 91200000 94800000 Gain KRT19P2 Barrett''s adenocarcinoma
9 74577 13 109100000 114142980 Gain Barrett''s adenocarcinoma
10 75797 13 24400000 26700000 Gain Barrett''s adenocarcinoma
11 79796 13 77800000 86500000 Gain SOX1 Barrett''s adenocarcinoma
12 81034 14 100400000 102200000 Gain SLC25A29 Barrett''s adenocarcinoma
13 88798 14 95400000 100400000 Gain TCL1A Barrett''s adenocarcinoma
14 88799 14 95400000 100400000 Gain TCL1B Barrett''s adenocarcinoma
15 107009 17 11200000 15900000 Loss RICH2 Barrett''s adenocarcinoma
16 114436 17 47600000 54900000 Gain CUEDC1 Barrett''s adenocarcinoma
17 115246 17 55600000 58400000 Gain LRRC37A3 Barrett''s adenocarcinoma
18 116543 17 6800000 11200000 Loss MYH13 Barrett''s adenocarcinoma
19 116544 17 6800000 11200000 Loss TP53 Barrett''s adenocarcinoma
20 122243 18 54400000 57100000 Loss Barrett''s adenocarcinoma
21 125938 19 16100000 19800000 Gain AP1M1 Barrett''s adenocarcinoma
22 127254 19 30200000 37100000 Gain ZNF536 Barrett''s adenocarcinoma
23 134771 2 106700000 108600000 Gain GCC2 Barrett''s adenocarcinoma
24 141056 2 205600000 209100000 Gain Barrett''s adenocarcinoma
25 144816 2 29800000 31900000 Gain ALK Barrett''s adenocarcinoma
26 151523 20 22300000 25700000 Gain SSTR4 Barrett''s adenocarcinoma
27 151524 20 22300000 25700000 Loss CST4 Barrett''s adenocarcinoma
28 152533 20 31500000 33900000 Gain CEP250 Barrett''s adenocarcinoma
29 154854 20 49200000 54400000 Gain CBLN4 Barrett''s adenocarcinoma
30 170891 3 161200000 169200000 Gain BCHE Barrett''s adenocarcinoma
31 172565 3 184200000 186000000 Gain MAGEF1 Barrett''s adenocarcinoma
32 172566 3 184200000 186000000 Gain MUC13 Barrett''s adenocarcinoma
33 172567 3 184200000 186000000 Gain VPS8 Barrett''s adenocarcinoma
34 177566 3 58500000 63700000 Loss Barrett''s adenocarcinoma
35 196847 5 172200000 176500000 Gain MSX2 Barrett''s adenocarcinoma
36 203652 6 1 2300000 Gain Barrett''s adenocarcinoma
37 204555 6 11200000 13500000 Gain PHACTR1 Barrett''s adenocarcinoma
38 205460 6 127300000 130400000 Gain C6orf190 Barrett''s adenocarcinoma
39 205461 6 127300000 130400000 Gain PTPRK Barrett''s adenocarcinoma
40 212308 6 36800000 40600000 Gain DNAH8 Barrett''s adenocarcinoma
41 219021 7 120900000 123600000 Loss SLC13A1 Barrett''s adenocarcinoma
42 219022 7 120900000 123600000 Loss TAS2R16 Barrett''s adenocarcinoma
43 225150 7 43300000 46600000 Gain RAMP3 Barrett''s adenocarcinoma
44 225833 7 50900000 53900000 Gain Barrett''s adenocarcinoma
45 227260 7 66100000 71800000 Gain CALN1 Barrett''s adenocarcinoma
46 227261 7 66100000 71800000 Gain WBSCR17 Barrett''s adenocarcinoma
47 227796 7 7200000 13300000 Gain ICA1 Barrett''s adenocarcinoma
48 231014 8 101600000 106100000 Gain ANKRD46 Barrett''s adenocarcinoma
49 231021 8 101600000 106100000 Gain RNF19 Barrett''s adenocarcinoma
50 232059 8 110600000 112200000 Gain PKHD1L1 Barrett''s adenocarcinoma

Expression for Barrett's Adenocarcinoma

Search GEO for disease gene expression data for Barrett's Adenocarcinoma.

Pathways for Barrett's Adenocarcinoma

Pathways related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.6 CDKN2A ERBB2 KRAS RAD51 TP53
2
Show member pathways
12.5 CDKN2A ERBB2 FHIT KRAS TP53
3
Show member pathways
12.47 ERBB2 KRAS PTGS2 TP53
4
Show member pathways
12.47 CDKN2A ERBB2 GSTT2 KRAS TP53
5
Show member pathways
12.34 ERBB2 KRAS RAD51 TP53
6 12.13 CDKN2A ERBB2 KRAS PTGS2 TP53
7 11.98 KRAS PTGS2 TP53
8 11.96 CDKN2A KRAS TP53
9 11.92 ERBB2 KRAS TP53
10 11.91 KRAS RAD51 TP53
11 11.89 CDKN2A ERBB2 GSTT2 KRAS PTGS2 RAD51
12
Show member pathways
11.85 ADIPOR1 ADIPOR2 KRAS TP53
13 11.75 CDKN2A KRAS TP53
14 11.68 CDKN2A ERBB2 KRAS TP53
15 11.64 FHIT PTGS2 TP53
16 11.47 ERBB2 KRAS TP53
17 11.38 KRAS RAD51 TP53
18 11.32 CDKN2A ERBB2 KRAS TP53
19 11.12 CDKN2A ERBB2 GSTT2 TP53
20 11.09 ERBB2 KRAS
21 11.07 RAD51 TP53
22 10.91 CDKN2A TP53
23
Show member pathways
10.9 CDKN2A TP53

GO Terms for Barrett's Adenocarcinoma

Cellular components related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.1 CDKN2A FHIT KRAS OGG1 RAD51 TP53

Biological processes related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.76 CDKN2A ERBB2 KRAS TP53
2 fatty acid metabolic process GO:0006631 9.65 ADIPOR1 ADIPOR2 PTGS2
3 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.49 FHIT TP53
4 positive regulation of cellular senescence GO:2000774 9.43 CDKN2A KRAS
5 Ras protein signal transduction GO:0007265 9.43 CDKN2A KRAS TP53
6 fatty acid oxidation GO:0019395 9.4 ADIPOR1 ADIPOR2
7 replicative senescence GO:0090399 9.37 CDKN2A TP53
8 regulation of fatty acid biosynthetic process GO:0042304 9.32 ADIPOR1 ADIPOR2
9 adiponectin-activated signaling pathway GO:0033211 9.16 ADIPOR1 ADIPOR2
10 negative regulation of immature T cell proliferation in thymus GO:0033088 8.96 CDKN2A ERBB2
11 negative regulation of cell growth GO:0030308 8.92 ADIPOR1 ADIPOR2 CDKN2A TP53

Molecular functions related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 ADIPOR1 ADIPOR2 ERBB2 FHIT RAD51 TP53
2 protein heterodimerization activity GO:0046982 9.62 ADIPOR1 ADIPOR2 ERBB2 TP53
3 nucleotide binding GO:0000166 9.56 ERBB2 FHIT KRAS RAD51
4 adiponectin binding GO:0055100 8.96 ADIPOR1 ADIPOR2
5 adipokinetic hormone receptor activity GO:0097003 8.62 ADIPOR1 ADIPOR2

Sources for Barrett's Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....